MX2022010780A - Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol. - Google Patents
Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol.Info
- Publication number
- MX2022010780A MX2022010780A MX2022010780A MX2022010780A MX2022010780A MX 2022010780 A MX2022010780 A MX 2022010780A MX 2022010780 A MX2022010780 A MX 2022010780A MX 2022010780 A MX2022010780 A MX 2022010780A MX 2022010780 A MX2022010780 A MX 2022010780A
- Authority
- MX
- Mexico
- Prior art keywords
- tapentadol
- dosage form
- prolonged release
- phosphoric acid
- acid salt
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 3
- 230000002035 prolonged effect Effects 0.000 title abstract 3
- 229960005126 tapentadol Drugs 0.000 title abstract 3
- -1 tapentadol phosphoric acid salt Chemical class 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 4
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract 1
- 235000013334 alcoholic beverage Nutrition 0.000 abstract 1
- QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical compound OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención hace referencia a una forma de dosificación farmacéutica que proporciona una liberación prolongada de Tapentadol, en donde Tapentadol está presente en forma de una sal con ácido fosfórico (ácido ortofosfórico), preferentemente, como sal de dihidrogenofosfato. La forma de dosificación de acuerdo con la invención proporciona propiedades de liberación prolongada mejoradas, es particularmente resistente contra la descarga de dosis inducida por etanol y, más allá de dicha resistencia, proporciona características de seguridad adicionales con respecto al uso concomitante de etanol, por ejemplo, bebidas alcohólicas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20160419.6A EP3875077B1 (en) | 2020-03-02 | 2020-03-02 | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
| EP20160420.4A EP3875079A1 (en) | 2020-03-02 | 2020-03-02 | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
| PCT/EP2021/055025 WO2021175773A1 (en) | 2020-03-02 | 2021-03-01 | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010780A true MX2022010780A (es) | 2022-09-26 |
Family
ID=74701506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010780A MX2022010780A (es) | 2020-03-02 | 2021-03-01 | Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol. |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4003318A1 (es) |
| BR (1) | BR112022017700A2 (es) |
| CO (1) | CO2022012567A2 (es) |
| DE (1) | DE202021003994U1 (es) |
| MX (1) | MX2022010780A (es) |
| PE (1) | PE20230105A1 (es) |
| WO (1) | WO2021175773A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022017700A2 (pt) | 2020-03-02 | 2023-01-17 | Gruenenthal Gmbh | Forma de dosagem fornecendo liberação prolongada de sal de ácido fosfórico de tapentadol |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL88083A (en) * | 1987-11-06 | 1992-11-15 | Tanabe Seiyaku Co | Controlled release pharmaceutical dosage form and its preparation |
| DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| PE20030527A1 (es) * | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
| ES2429436T3 (es) * | 2002-02-21 | 2013-11-14 | Otsuka Pharmaceutical Co., Ltd. | Preparaciones de liberación lenta y procedimiento para la producción de las mismas |
| PL1786403T3 (pl) | 2004-07-01 | 2013-10-31 | Gruenenthal Gmbh | Doustna postać dawki zabezpieczona przed nadużywaniem zawierająca (1R, 2R)-3-(3-dimetyloamino-1-etylo0-2-metylo-propylo)fenol |
| CN101568329A (zh) | 2006-10-27 | 2009-10-28 | 詹森药业有限公司 | 干燥颗粒药用组合物及其生产方法 |
| AU2009207796B2 (en) | 2008-01-25 | 2014-03-27 | Grunenthal Gmbh | Pharmaceutical dosage form |
| PE20190391A1 (es) | 2008-10-30 | 2019-03-13 | Gruenenthal Chemie | Formas de dosificacion del tapentadol novedosas y potentes |
| DK3656765T3 (da) | 2010-07-23 | 2021-06-14 | Gruenenthal Gmbh | Salte eller co-krystaller af 3-(3-dimethylamin-1-ethyl-2-methyl-propyl)-phenol |
| WO2012051246A1 (en) | 2010-10-12 | 2012-04-19 | Ratiopharm Gmbh | Tapentadol hydrobromide and crystalline forms thereof |
| CN105682643B (zh) | 2013-07-12 | 2019-12-13 | 格吕伦塔尔有限公司 | 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型 |
| US20160136112A1 (en) | 2013-08-02 | 2016-05-19 | Ratiopharm Gmbh | Composition comprising tapentadol in a dissolved form |
| EP2942054A1 (en) | 2014-05-09 | 2015-11-11 | G.L. Pharma GmbH | Slow-release pharmaceutical formulation |
| ES2937740T3 (es) | 2016-04-19 | 2023-03-30 | Ratiopharm Gmbh | Fosfato de tapentadol cristalino |
| EP3630074B1 (en) | 2017-05-29 | 2023-10-25 | Grünenthal GmbH | Multiparticulate oral dosage form providing prolonged release of tapentadol |
| BR112022017700A2 (pt) | 2020-03-02 | 2023-01-17 | Gruenenthal Gmbh | Forma de dosagem fornecendo liberação prolongada de sal de ácido fosfórico de tapentadol |
-
2021
- 2021-03-01 BR BR112022017700A patent/BR112022017700A2/pt unknown
- 2021-03-01 EP EP21707730.4A patent/EP4003318A1/en active Pending
- 2021-03-01 WO PCT/EP2021/055025 patent/WO2021175773A1/en not_active Ceased
- 2021-03-01 MX MX2022010780A patent/MX2022010780A/es unknown
- 2021-03-01 DE DE202021003994.5U patent/DE202021003994U1/de active Active
- 2021-03-01 PE PE2022001894A patent/PE20230105A1/es unknown
-
2022
- 2022-09-02 CO CONC2022/0012567A patent/CO2022012567A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022017700A2 (pt) | 2023-01-17 |
| WO2021175773A1 (en) | 2021-09-10 |
| EP4003318A1 (en) | 2022-06-01 |
| PE20230105A1 (es) | 2023-01-25 |
| CO2022012567A2 (es) | 2022-09-09 |
| DE202021003994U1 (de) | 2022-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014205529B2 (en) | Methods and compositions for treatment of demyelinating diseases | |
| Li et al. | Autophagy regulators as potential cancer therapeutic agents: a review | |
| BR112014028633A8 (pt) | tratamento de amd usando sflt-1 de aav | |
| JP5902628B2 (ja) | 相乗的抗ウイルス組成物及びその使用 | |
| MX347227B (es) | Composicion farmaceutica o nutraceutica con liberacion sostenida caracteristica y con resistencia contra la influencia del etanol. | |
| WO2009152189A8 (en) | Low dose topiramate/phentermine compostion and methods of use thereof | |
| MX2008010155A (es) | Composiciones virucidales que contienen metal y sus usos. | |
| MX390570B (es) | Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. | |
| WO2012064897A3 (en) | Bicyclic and tricyclic inhibitors of sumoylation enzymes and methods for their use | |
| MX2022010780A (es) | Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol. | |
| HRP20201703T1 (hr) | Liječenje kokcidioze intramuskularnim triazinskim pripravcima | |
| WO2019241306A3 (en) | Combination therapy with neoantigen vaccine | |
| JP2016510343A5 (es) | ||
| EP1948147A2 (en) | Compositions useful for prevention and treatment of common cold and influenza-like symptoms | |
| CO2023008265A2 (es) | Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación | |
| CN111315374A (zh) | 合成的赖氨酸类似物和模拟物的用于抗病毒用途的方法和组合物 | |
| Yoo et al. | FRI0143 A randomized, double-blind, phase 3 study demonstrates clinical equivalence of CT-P13 to infliximab when co-administered with methotrexate in patients with active rheumatoid arthritis | |
| MX2017013643A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz. | |
| MX2024000202A (es) | Composicion farmaceutica y uso de la misma. | |
| PH12023553121A1 (en) | Benzamide derivative, method for preparing same, and pharmaceutical composition for prevention or treatment of cancer containing same as active ingredient | |
| MX393290B (es) | Composicion para el tratamiento de la osteoartritis | |
| MX2019001738A (es) | Formulacion de efedrina y sus derivados resistente a la manipulacion. | |
| US20220061315A1 (en) | Persistent sanitizer | |
| US20150164928A1 (en) | Pharmaceutical composition for the regeneration of the liver | |
| CN105451729A (zh) | 抗病毒化合物和组合物 |